Company: AGIO
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001193125-25-004943
Chunk: 0

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On January 13, 2025, Agios Pharmaceuticals, Inc. (the “ Company”) issued a press release outlining its anticipated 2025 milestones, which will be discussed at the Company’s presentation at the 43rdAnnual J. P. Morgan Healthcare Conference on January 15, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated herein by reference. The slides to be presented by the Company at the 43rdAnnual J. P. Morgan Healthcare Conference are furnished as Exhibit 99.2 to this Current Report on Form 8-K andare incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.